Rosacea Clinical Trial
Official title:
A Randomized, Double-blind Trial Evaluating the Effects of Treatment With DFD-29 Capsules 40 mg QD in Comparison to Placebo on Microbial Flora in Healthy Adult Human Subjects, When Administered Over a Period of 16 Weeks.
Verified date | August 2023 |
Source | Journey Medical Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
Status | Completed |
Enrollment | 60 |
Est. completion date | May 30, 2023 |
Est. primary completion date | May 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male or non-pregnant, non-lactating female aged = 18 and = 65 years. 2. Subjects must have understood, and signed IRB/IEC approved written ICF. 3. Subjects must be willing to refrain from using all other antibiotics during the 16-week treatment period, other than the IP. 4. Women of childbearing potential* must not be pregnant or lactating at the time of screening visit as documented by a negative urine pregnancy test. 5. Women of childbearing potential must be willing to use an acceptable form of birth control during the trial from the day of the first dose administration to 30 days after the last administration of trial drug. 6. All male subjects must agree to use accepted methods of birth control with their partners, throughout the study and until 30 days after the last administration of trial drug. 7. Subjects must be in good health and free from any clinically significant disease, which may interfere with the evaluation of microbiota or the administration of the IP. Exclusion Criteria: 1. Female subjects who are pregnant, lactating or planning to become pregnant during trial participation. 2. History of allergy or known sensitivity to minocycline, doxycycline, other tetracycline, or any component of the study medication. 3. Clinically significant abnormal laboratory test results that, in the opinion of the Investigator, would compromise the subject's safety or ability to participate in the trial 4. History of organ transplant requiring immunosuppression, HIV, or other immune compromised state. 5. History of lupus-like syndrome, autoimmune hepatitis, vasculitis, or serum sickness. 6. Any clinically significant condition that, in the opinion of the Investigator, would interfere with the study evaluations or would place the trial subject at undue safety risk. 7. Subjects with an active acute or chronic systemic infections 8. Subjects with planned surgery during the trial or within 30 days after the last dose administration 9. Subjects who cannot avoid excessive exposure to UV radiation (use of tanning booths or extended /occupational exposure to sunlight) 10. Subjects that have a medical history of photosensitivity or hyperpigmentation 11. Female subjects with medical history within 3 months prior to randomization of having vaginitis or that use a vaginal douche or vaginal cleaning agent within 48 hours of any visit 12. Subjects who used the following 1. Non-tetracycline antibiotics (systemic) within 6 weeks prior to Baseline (BL) 2. Tetracycline antibiotics (systemic) within 3 months prior to BL 13. Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates) within one year prior to screening 14. Subjects who have been treated with systemic retinoids or therapeutic Vitamin A supplements > 10,000 IU/ day (multivitamin tablets are allowed) within 180 days prior to the BL 15. Subjects who are on anti-coagulants or those likely to require anti-coagulants during the trial period 16. Subjects who have used methoxyflurane or other nephrotoxic drugs (in the opinion of the Investigator) within the past 30 days of BL 17. Subjects who have used topical retinoids or topical antibiotics to the face 30 days prior to BL 18. Subjects who have used on their facial skin within 30 days prior to BL topical corticosteroids, topical anti-mycotic, topical azelaic acid or ivermectin 19. Subjects who have participated in an investigational drug trial (i.e., subjects have been treated with an investigational drug) within 30 days prior to BL or where sufficient washout period has not been achieved; whichever period is longer. 20. Subjects having symptoms of COVID-19 or have had close contact with someone with suspected or confirmed SARS-CoV-2 infection within 10 days prior to screening or who are at high risk of SARS-CoV-2 infection. |
Country | Name | City | State |
---|---|---|---|
United States | 3A Research, LLC | El Paso | Texas |
United States | 3A Research, LLC | Las Cruces | New Mexico |
Lead Sponsor | Collaborator |
---|---|
Journey Medical Corporation | Dr. Reddy's Laboratories Limited |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in the number of colony forming units (CFUs) of microbial species. | Change in the colony forming units (CFUs) of microbial species colonized from skin, gastrointestinal or vaginal swabs from Baseline (BL) to Week 16 in comparison of DFD-29 versus Placebo treatment groups | Baseline to Week 16 | |
Primary | Changes in MIC90 of selected colonized microbial species. | Changes in MIC90 of the selected colonized microbial species to minocycline in the comparison of DFD-29 group versus Placebo treatment groups. | Baseline to Week 16. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02601963 -
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT02249065 -
Mirvaso in Use Study
|
Phase 4 | |
Completed |
NCT02292797 -
Assessment of the Rosacea Prevalence in the General Population
|
N/A | |
Completed |
NCT01659853 -
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
|
Phase 3 | |
Completed |
NCT01426269 -
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
|
Phase 4 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Terminated |
NCT04336163 -
Skin Imaging to Inform Laser Treatments
|
N/A | |
Recruiting |
NCT04108897 -
Analysis of the Microbiome in Rosacea
|
Early Phase 1 | |
Completed |
NCT03872050 -
Deep Phenotyping of Rosacea and Migraine
|
||
Active, not recruiting |
NCT06033352 -
Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea
|
Phase 2 | |
Completed |
NCT03263273 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT04508660 -
CGB-400 for the Reduction of Facial Redness
|
Phase 1 | |
Completed |
NCT04508205 -
CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes
|
Phase 1 | |
Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A | |
Active, not recruiting |
NCT03211585 -
EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA
|
N/A | |
Completed |
NCT02576860 -
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
|
Phase 3 | |
Completed |
NCT02637232 -
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
|
||
Completed |
NCT02576847 -
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
|
Phase 3 | |
Completed |
NCT02583009 -
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea
|
Phase 2 | |
Completed |
NCT01993446 -
A Safety and Efficacy Study of DRM02 in Subjects With Rosacea
|
Phase 2 |